Rapid identification of YVDD mutants of hepatitis B virus using smart amplification process with competition probe

Acta Virologica

Volumn 55, Issue 4, 2011, Pages 295-302

  Yang, Jin ^a,b   Li, Jie ^a   Lou, Guo Qiang ^c   Wu, Li Juan ^d   Feng, Chen ^b   Wu, Nan Ping ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b BLOOD CENTER OF ZHEJIANG PROVINCE   (China)

^c HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^d TAIZHOU UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Lamivudine; SMAP; YVDD mutant

Indexed keywords

LAMIVUDINE;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; GENE AMPLIFICATION; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; MOLECULAR PROBE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SMART AMPLIFICATION PROCESS; VIRUS MUTANT;

ANTIVIRAL AGENTS; CODON; DNA PRIMERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POINT MUTATION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

HEPATITIS B VIRUS;

EID: 84862944026     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2011_04_295     Document Type: Article

References (33)

1. Aomori T, Yamamoto K, Oguchi-Katayama A, Kawai Y, Ishidao T, Mitani Y, Kogo Y, Lezhava A, Fujita Y, Obayashi K, Nakamura K, Kohnke H, Wadelius M, Ekstrom L, Skogastierna C, Rane A, Kurabayashi M, Murakami M, Cizdziel PE, Hayashizaki Y, Horiuchi R (2009): Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2. Clin. Chem. 55, 804-812. http://dx.doi.org/10.1373/clinchem.2008.115295
2. Araki T, Shimizu K, Nakamura K, Nakamura T, Mitani Y, Obayashi K, Fujita Y, Kakegawa S, Miyamae Y, Kaira K, Ishidao T, Lezhava A, Hayashizaki Y, Takeyoshi I, Yamamoto K (2010): Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. J. Mol. Diagn. 12, 118-124. http://dx.doi.org/10.2353/jmoldx.2010.090081
3. Fournier C, Zoulim F (2007): Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin. Liver Dis. 11, 869-892. http://dx.doi.org/10.1016/j.cld.2007.08.013
4. Ghany M, Liang TJ (2007): Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132, 1574-1585. http://dx.doi.org/10.1053/j.gastro.2007.02.039
5. Ghany MG, Doo EC (2009): Antiviral resistance and hepatitis B therapy. Hepatology 49, S174-S184. http://dx.doi.org/10.1002/hep.22900
6. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C (2000): Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32, 847-851. http://dx.doi.org/10.1053/jhep.2000.17915
7. Hoshi K, Takakura H, Mitani Y, Tatsumi K, Momiyama N, Ichikawa Y, Togo S, Miyagi T, Kawai Y, Kogo Y, Kikuchi T, Kato C, Arakawa T, Uno S, Cizdziel PE, Lezhava A, Ogawa N, Hayashizaki Y, Shimada H (2007): Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin. Cancer Res. 13, 4974-4983. http://dx.doi.org/10.1158/1078-0432.CCR-07-0509
8. Hosseini SY, Sabahi F, Amini-Bavil-Olyaee S, Alavian SM, Merat S (2006): A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains. J. Virol. Methods 137, 298-303. http://dx.doi.org/10.1016/j.jviromet.2006.07.008
9. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Chen CJ (2007): Risk and predictors of mortality associated with chronic hepatitis B infection. Clin. Gastroenterol. Hepatol. 5, 921-931. http://dx.doi.org/10.1016/j.cgh.2007.06.015
10. Inoue Y, Mori T, Toyoda Y, Sakurai A, Ishikawa T, Mitani Y, Hayashizaki Y, Yoshimura Y, Kurahashi H, Sakai Y (2010): Correlation of axillary osmidrosis to a SNP in the ABCC11 gene determined by the Smart Amplification Process (SmartAmp) method. J. Plast. Reconstr. Aesthet. Surg.63, 1369-1374. http://dx.doi.org/10.1016/j.bjps.2009.06.029
11. Jardi R, Buti M, Rodriguez-Frias F, Cotrina M, Costa X, Pascual C, Esteban R, Guardia J (1999): Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J. Virol. Methods 83, 181-187. http://dx.doi.org/10.1016/S0166-0934(99)00125-1
12. Kawai Y, Kikuchi T, Mitani Y, Kogo Y, Itoh M, Usui K, Kanamori H, Kaiho A, Takakura H, Hoshi K, Cizdziel PE, Hayashizaki Y (2008): Sensitive detection of EGFR mutations using a competitive probe to suppress background in the SMart Amplification Process. Biologicals 36, 234-238. http://dx.doi.org/10.1016/j.biologicals.2008.01.003
13. Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, Chung HJ, Yoo W, Kim SO, Hong SP (2005): Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir. Ther. 10, 441-449.
14. Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB (2008): Direct detection of lamivudineresistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J. Virol. Methods 149, 76-84. http://dx.doi.org/10.1016/j.jviromet.2008.01.003
15. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L (2003): Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36, 687-696. http://dx.doi.org/10.1086/368083
16. Li ZG, Chen LY, Huang J, Qiao P, Qiu JM, Wang SQ (2005): Quantification of the relative levels of wild-type and lamivudineresistant mutant virus in serum of HBV-infected patients using microarray. J. Viral Hepat. 12, 168-175. http://dx.doi.org/10.1111/j.1365-2893.2005.00562.x
17. Liaw YF (2007): Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? Hepatology 45, 266-268. http://dx.doi.org/10.1002/hep.21546
18. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J (2004): Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521-1531. http://dx.doi.org/10.1056/NEJMoa033364
19. Lindstrom A, Odeberg J, Albert J (2004): Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J. Clin. Microbiol. 42, 4788-4795. http://dx.doi.org/10.1128/JCM.42.10.4788-4795.2004
20. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M (2003): Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125, 1714-1722. http://dx.doi.org/10.1053/j.gastro.2003.09.033
21. Lok AS, McMahon BJ (2009): Chronic hepatitis B: update 2009. Hepatology 50, 661-662. http://dx.doi.org/10.1002/hep.23190
22. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C (2007): Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46, 254-265. http://dx.doi.org/10.1002/hep.21698
23. Lupo J, Larrat S, Hilleret MN, Germi R, Boyer V, Nicod S, Bargues G, Leroy V, Seigneurin JM, Zarski JP, Morand P (2009): Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. J. Virol. Methods 156, 52-58. http://dx.doi.org/10.1016/j.jviromet.2008.10.028
24. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, Simen BB, Egholm M, Shafer RW (2009): Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J. Infect. Dis. 199, 1275-1285. http://dx.doi.org/10.1086/597808
25. Mitani Y, Lezhava A, Kawai Y, Kikuchi T, Oguchi-Katayama A, Kogo Y, Itoh M, Miyagi T, Takakura H, Hoshi K, Kato C, Arakawa T, Shibata K, Fukui K, Masui R, Kuramitsu S, Kiyotani K, Chalk A, Tsunekawa K, Murakami M, Kamataki T, Oka T, Shimada H, Cizdziel PE, Hayashizaki Y (2007): Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nat. Methods 4, 257-262. http://dx.doi.org/10.1038/nmeth1007
26. Miyamae Y, Shimizu K, Mitani Y, Araki T, Kawai Y, Baba M, Kakegawa S, Sugano M, Kaira K, Lezhava A, Hayashizaki Y, Yamamoto K, Takeyoshi I (2010): Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. J. Mol. Diagn. 12, 257-264. http://dx.doi.org/10.2353/jmoldx.2010.090105
27. Reinis M, Vandasova J, Stankova M, Linka M, Bruckova M (2001): Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing. Acta Virol. 45, 279-286.
28. Ren WC, Wang CM, Cai YY (2009): Loop-mediated isothermal amplification for rapid detection of acute viral necrobiotic virus in scallop Chlamys farreri. Acta Virol. 53, 161-167. http://dx.doi.org/10.4149/av_2009_03_161
29. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR (2009): Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J. Virol. 83, 1718-1726. http://dx.doi.org/10.1128/JVI.02011-08
30. Tatsumi K, Mitani Y, Watanabe J, Takakura H, Hoshi K, Kawai Y, Kikuchi T, Kogo Y, Oguchi-Katayama A, Tomaru Y, Kanamori H, Baba M, Ishidao T, Usui K, Itoh M, Cizdziel PE, Lezhava A, Ueda M, Ichikawa Y, Endo I, Togo S, Shimada H, Hayashizaki Y (2008): Rapid screening assay for KRAS mutations by the modified smart amplification process. J. Mol. Diagn. 10, 520-526. http://dx.doi.org/10.2353/jmoldx.2008.080024
31. Vincenti D, Solmone M, Garbuglia AR, Iacomi F, Capobianchi MR (2009): A sensitive direct sequencing assay based on nested PCR for the detection of HBV polymerase and surface glycoprotein mutations. J. Virol. Methods 159, 53-57. http://dx.doi.org/10.1016/j.jviromet.2009.02.027
32. Watanabe J, Mitani Y, Kawai Y, Kikuchi T, Kogo Y, Oguchi-Katayama A, Kanamori H, Usui K, Itoh M, Cizdziel PE, Lezhava A, Tatsumi K, Ichikawa Y, Togo S, Shimada H, Hayashizaki Y (2007): Use of a competitive probe in assay design for genotyping of the UGT1A1 *28 microsatellite polymorphism by the smart amplification process. Biotechniques 43, 479-484. http://dx.doi.org/10.2144/000112563
33. Yeon JE (2008): Technique for the early detection of drug-resistant HBV DNA during antiviral therapy. Intervirology 51 (Suppl. 1), 7-10. http://dx.doi.org/10.1159/000122593